{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T10:48:24Z","timestamp":1790938104104,"version":"4.1.0"},"reference-count":51,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Central nervous system lymphoma (CNSL) is rare and aggressive, which has high rates of recurrence and fatality. At present, there does not exist any standard treatment for the relapsed\/refractory (R\/R) CNSL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively analyzed 4 patients with R\/R CNSL, who were treated with gloftamab combined with lenalidomide between October 2024 and June 2025 at the First Affiliated Hospital of Chongqing Medical University. Treatment response was assessed by brain magnetic resonance imaging and cerebrospinal fluid cytology every two cycles.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The 4 R\/R CNSL patients include 1 male and 3 females, with the mean age of 58 years (range: 51~69 years). Their clinical manifestations at relapse included headache, stupor, listlessness, lethargy, nausea, poor appetite, weak limbs, walking disorder, slurred speech and visual impairment. The mean relapse time was 5 months (range 3~8 months) after the last treatment. After 2 cycles of treatment, all patients achieved rapid remission (2 in CRu and 2 in PR), the overall response rate was 100% (4\/4). They got deep remission after 4 cycles (3 in CR\/CRu, 1 in PR). No patient experienced cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome nor hematological toxicity of grade 3 or above. Neither liver nor kidney dysfunction was observed. No treatment discontinuation occurred due to adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The glofitamab-lenalidomide combination showed promising activity and excellent tolerability in R\/R CNSL, potentially addressing the critical need for effective salvage regimens.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2025.1685271","type":"journal-article","created":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T05:21:37Z","timestamp":1762147297000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Relapsed or refractory central nervous system lymphoma successfully treated by glofitamab combined with lenalidomide"],"prefix":"10.3389","volume":"15","author":[{"given":"Yin-yin","family":"Peng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-qiong","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-024-01609-3","article-title":"CAR T\u2212cell therapy for central nervous system lymphoma","volume":"26","author":"Houillier","year":"2024","journal-title":"Curr Oncol Rep"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2025.2458214","article-title":"CAR-T cell therapy in the treatment of relapsed or refractory primary central nervous system lymphoma: recent advances and challenges","volume":"66","author":"Xiong","year":"2025","journal-title":"Leuk Lymph"},{"key":"B3","doi-asserted-by":"publisher","first-page":"20406207241259010","DOI":"10.1177\/20406207241259010","article-title":"Updates of primary central nervous system lymphoma","volume":"15","author":"Wu","year":"2024","journal-title":"Ther Adv Hematol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the world health organization classification of haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"B5","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1080\/10428190802311441","article-title":"Primary lymphoma of the central nervous system: epidemiology, pathology and current approaches to diagnosis, prognosis and treatment","volume":"49","author":"Rubenstein","year":"2008","journal-title":"Leuk Lymph"},{"key":"B6","doi-asserted-by":"publisher","first-page":"103341","DOI":"10.1016\/j.critrevonc.2021.103341","article-title":"Prognostic models in primary central nervous system lymphoma patients: A systematic review","volume":"161","author":"Jelicic","year":"2021","journal-title":"Crit Rev Oncol Hematol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-023-12143-w","article-title":"Primary central nervous system lymphoma","volume":"271","author":"de Koning","year":"2024","journal-title":"J Neurol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020008377","article-title":"Primary central nervous system lymphoma","volume":"140","author":"Schaff","year":"2022","journal-title":"Blood"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2022.281457","article-title":"Prevention and management of secondary central nervous system lymphoma","volume":"108","author":"Bobillo","year":"2023","journal-title":"Haematologica"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023020168","article-title":"How I treat secondary CNS involvement by aggressive lymphomas","volume":"142","author":"Alderuccio","year":"2023","journal-title":"Blood"},{"key":"B11","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ejca.2018.01.073","article-title":"Treatment strategies, outcomes, and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B- cell lymphoma","volume":"93","author":"El-Galaly","year":"2018","journal-title":"Eur J Cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-013-1403-z","article-title":"Treatment outcome of relapsed\/refractory primary central nervous system diffuse large B-cell lymphoma: a single-center experience of autologous stem cell transplantation","volume":"98","author":"Choi","year":"2013","journal-title":"Int J Hematol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.14382","article-title":"Favourable outcome of relapsed PCNSL among transplant eligble patients","volume":"114","author":"Pellonper\u00e4","year":"2025","journal-title":"Eur J Haematol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s11910-024-01389-0","article-title":"Advances in primary central nervous system lymphoma","volume":"25","author":"Therkelsen","year":"2024","journal-title":"Curr Neurol Neurosci Rep"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-09-875732","article-title":"Phase 1b trial of an ibrutinib-based combination therapy in recurrent\/refractory CNS lymphoma","volume":"133","author":"Grommes","year":"2019","journal-title":"Blood"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-01-764209","article-title":"PD-1 blockade with nivolumab in relapsed\/refractory primary central nervous system and testicular lymphoma","volume":"129","author":"Nayak","year":"2017","journal-title":"Blood"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.9897","article-title":"Phase II trial of temsirolimus for relapsed\/refractory primary CNS lymphoma","volume":"34","author":"Korfel","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.181636","article-title":"Promising activity of selinexor in the treatment of a patient with refractory diffuse large B-cell lymphoma and central nervous system involvement","volume":"103","author":"Bobillo","year":"2018","journal-title":"Haematologica"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2017014845","article-title":"Phase 1 investigation of lenalidomide\/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma","volume":"2","author":"Rubenstein","year":"2018","journal-title":"Blood Adv"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.938421","article-title":"Pemetrexed plus lenalidomide for relapsed\/refractory primary central nervous system lymphoma: A prospective single-arm phase II study","volume":"12","author":"Ma","year":"2022","journal-title":"Front Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.901797","article-title":"Orelabrutinib combined with lenalidomide and immunochemotherapy for relapsed\/refractory primary central nervous system lymphoma: A retrospective analysis of case series","volume":"12","author":"Yang","year":"2022","journal-title":"Front Oncol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s13045-024-01606-w","article-title":"Phase IB part of LOC-R01, a LOC network non-comparative randomized phase IB\/II study testing R-MPV in combination with escalating doses of lenalidomide or ibrutinib for newly diagnosed primary central nervous system lymphoma (PCNSL) patients","volume":"17","author":"Alcantara","year":"2024","journal-title":"J\u00a0Hematol Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1097\/BS9.0000000000000095","article-title":"Immune targeted therapy for diffuse large B cell lymphoma","volume":"3","author":"Zheng","year":"2021","journal-title":"Blood Sci"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/cts.70250","article-title":"CD20\u00d7CD3 bispecific antibodies in B-NHL: A review of translational science, pharmacokinetics, pharmacodynamics, and dose strategy in clinical research","volume":"18","author":"Zhu","year":"2025","journal-title":"Clin Transl Sci"},{"key":"B25","doi-asserted-by":"publisher","first-page":"77.e1","DOI":"10.1016\/j.jtct.2023.10.017","article-title":"Real-world outcomes with chimeric antigen receptor T cell therapies in large B cell lymphoma: A systematic review and meta-analysis","volume":"30","author":"Jacobson","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/s13402-023-00833-6","article-title":"Lenalidomide overcomes the resistance to third-generation CD19-CAR-T cell therapy in preclinical models of diffuse large B-cell lymphoma","volume":"46","author":"Jin","year":"2023","journal-title":"Cell Oncol (Dordr)"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.13.524","article-title":"Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma","volume":"23","author":"Abrey","year":"2005","journal-title":"J Clin Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1177\/1740774520975120","article-title":"Composite grading algorithm for the National Cancer Institute\u2019s Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)","volume":"18","author":"Basch","year":"2021","journal-title":"Clin Trials"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transpl"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1212\/CON.0000000000000936","article-title":"Central nervous system lymphomas","volume":"26","author":"Grommes","year":"2020","journal-title":"Continuum (Minneap Minn)"},{"key":"B31","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1093\/neuonc\/noac196","article-title":"European Association of Neuro-Oncology (EANO) guidelines for treatment of primary central nervous system lymphoma (PCNSL)","volume":"25","author":"Hoang-Xuan","year":"2023","journal-title":"Neuro Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2024.531","article-title":"Nivolumab in relapsed or refractory primary central nervous system lymphoma: multicenter, retrospective study[J","volume":"57","author":"Yi","year":"2025","journal-title":"Cancer Res Treat"},{"key":"B33","doi-asserted-by":"publisher","first-page":"99","DOI":"10.3390\/neurolint14010009","article-title":"Ibrutinib in refractory or relapsing primary central nervous system lymphoma: A systematic review","volume":"14","author":"Nepal","year":"2022","journal-title":"Neurol Int"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1055\/s-0043-1776783","article-title":"Central nervous system lymphoma","volume":"43","author":"Shah","year":"2023","journal-title":"Semin Neurol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2018.11.018","article-title":"Autologous stem-cell transplantation for primary central nervous system lymphoma: systematic review and meta-analysis","volume":"19","author":"Alnahhas","year":"2019","journal-title":"Clin Lymph Myeloma Leuk"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-021-00921-5","article-title":"Central nervous system lymphoma: novel therapies","volume":"23","author":"Fortin Ensign","year":"2022","journal-title":"Curr Treat Options Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.2176\/jns-nmc.2022-0134","article-title":"A case of relapsed primary central nervous system lymphoma treated with CD19-directed chimeric antigen receptor T cell therapy","volume":"9","author":"Mizuta","year":"2022","journal-title":"NMC Case Rep J"},{"key":"B38","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.clml.2022.09.008","article-title":"Chimeric antigen receptor T-cell (CAR T-cell) therapy for primary and secondary central nervous system lymphoma: A systematic review of literature","volume":"23","author":"Asghar","year":"2023","journal-title":"Clin Lymph Myeloma Leuk"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.01306","article-title":"CAR T-cell therapy is effective but not long-lasting in B-cell lymphoma of the brain","volume":"10","author":"Li","year":"2020","journal-title":"Front Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.03175","article-title":"Glofitamab, a novel, bivalent CD20-targeting T-cell-engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma: A phase I trial","volume":"39","author":"Hutchings","year":"2021","journal-title":"J Clin Oncol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206913","article-title":"Glofitamab for relapsed or refractory diffuse large B-cell lymphoma","volume":"387","author":"Dickinson","year":"2022","journal-title":"N Engl J Med"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)01774-4","article-title":"Glofitamab\u2002plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma\u2002(STARGLO): a global phase 3, randomised, open-label trial","volume":"404","author":"Abramson","year":"2024","journal-title":"Lancet"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1002\/hon.3174","article-title":"Glofitamab in relapsed\/refractory diffuse large B-cell lymphoma: Real-world data","volume":"41","author":"Birtas Atesoglu","year":"2023","journal-title":"Hematol Oncol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024024168","article-title":"Glofitamab stimulates immune cell infiltration of CNS tumors and induces clinical responses in secondary CNS lymphoma","volume":"144","author":"Godfrey","year":"2024","journal-title":"Blood"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/10428194.2025.2549519","article-title":"Glofitamab induces deep and rapid response in relapsed primary central nervous system lymphoma","volume":"2","author":"Wang","year":"2025","journal-title":"Leuk Lymph"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.756728","article-title":"Efficacy and safety of lenalidomide monotherapy for relapsed\/refractory diffuse large B cell lymphoma: systematic review and meta-analysis","volume":"11","author":"Li","year":"2021","journal-title":"Front Oncol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.238162","article-title":"Treatment of patients with MYC rearrangement positive large B-cell lymphoma with R-CHOP plus lenalidomide: results of a multicenter HOVON phase II trial","volume":"105","author":"Chamuleau","year":"2020","journal-title":"Haematologica"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2023.05.040","article-title":"Cerebral delivery of redox-responsive lenalidomide prodrug plus methotrexate for primary central nerve system lymphoma combination therapy","volume":"359","author":"Liu","year":"2023","journal-title":"J Ctrl Rel"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz032","article-title":"Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed\/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective \u2018proof of concept\u2019 phase II study of the French Oculo-Cerebral lymphoma (LOC) Network and the Lymphoma Study Association (LYSA)","volume":"30","author":"Ghesquieres","year":"2019","journal-title":"Ann Oncol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-22-0498","article-title":"IMiDs augment CD3-bispecific antibody-induced CD8+ T-cell cytotoxicity and expansion by enhancing IL2 production","volume":"22","author":"Li","year":"2023","journal-title":"Mol Cancer Ther"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.73.2578","article-title":"Maintenance lenalidomide for large-cell lymphoma: who really benefits","volume":"35","author":"Witzig","year":"2017","journal-title":"J Clin Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1685271\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T05:21:37Z","timestamp":1762147297000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1685271\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,3]]},"references-count":51,"alternative-id":["10.3389\/fonc.2025.1685271"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1685271","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,3]]},"article-number":"1685271"}}